Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China
Authors:
- 14 October 2019
- journal article
- research article
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 16 (1) , 89-98
Abstract
Macrophage activation syndrome (MAS) is a major cause of morbidity and mortality in pediatric rheumatology. We aimed to further understand the clinical features, treatment, and outcome of MAS in China.Keywords
Funding Information
- Zhejiang Basic Public Welfare Research Project (LGF19H100002)
This publication has 46 references indexed in Scilit:
- Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosisArthritis Research & Therapy, 2012
- Macrophage Activation Syndrome in the Acute Phase of Kawasaki DiseaseJournal of Pediatric Hematology/Oncology, 2010
- Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty‐eight patientsArthritis & Rheumatism, 2009
- Review: Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?Lupus, 2007
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitidesAnnals of the Rheumatic Diseases, 2006
- An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM)Rheumatology, 2006
- Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritisThe Journal of Pediatrics, 2005
- Macrophage activation syndrome: a potentially fatal complication of rheumatic disordersArchives of Disease in Childhood, 2001
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997